Skip to main content

Aalto Bio Reagents Recombinant SARS-CoV-2 Spike Proteins

Dublin-based Aalto Bio Reagents has released a range of recombinant SARS-CoV-2 spike (S) proteins for diagnostic test manufacturers, vaccine developers, and researchers globally. The S protein is the main antigenic component that is responsible for inducing host immune responses and neutralizing antibodies, making it the principal focus of therapeutic and vaccine design for COVID-19. When used solely or in combination with Aalto's new insect-derived nucleocapsid protein (N), the company's S1-S2 chimeric glycoprotein has demonstrated excellent reactivity in ELISA for the detection of IgA, IgG and IgM antibodies against SARS-CoV-2, the company said.